TY - JOUR
T1 - Extracellular vesicles as personalized medicine
AU - Beetler, Danielle J.
AU - Di Florio, Damian N.
AU - Bruno, Katelyn A.
AU - Ikezu, Tsuneya
AU - March, Keith L.
AU - Cooper, Leslie T.
AU - Wolfram, Joy
AU - Fairweather, De Lisa
N1 - Funding Information:
The authors declare that there are no conflicts of interest. The work has been performed with partial support from National Institutes of Health (NIH) grant TL1 TR002380 (to DJB, DND), U54 TR002377 (to DJB, DND, DF), National Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356, R21 AI154927 (to DF), R21 AI152318 (to JW and DF), and R21 AI163302 (to KAB), National Institute on Aging (NIA) grants R01 AG072719, R01 AG054199, R01 AG067763, R01 AG066429, R01 AG054672 (to TI), National Heart, Lung and Blood Institute (NHLBI) grant R01 HL164520 (to DF), American Heart Association grant 20TPA35490415 (to DF), a Mayo Clinic Team Science Award (to DF), the Mayo Clinic Center for Regenerative Medicine in Florida (to JW and DF), the University of Queensland grant (to JW), and Ionis Pharmaceuticals Ion-ARPA Operation Payload Delivery grant (to JW). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Publisher Copyright:
© 2022 The Authors
PY - 2023/6
Y1 - 2023/6
N2 - Extracellular vesicles (EVs) are released from all cells in the body, forming an important intercellular communication network that contributes to health and disease. The contents of EVs are cell source-specific, inducing distinct signaling responses in recipient cells. The specificity of EVs and their accumulation in fluid spaces that are accessible for liquid biopsies make them highly attractive as potential biomarkers and therapies for disease. The duality of EVs as favorable (therapeutic) or unfavorable (pathological) messengers is context dependent and remains to be fully determined in homeostasis and various disease states. This review describes the use of EVs as biomarkers, drug delivery vehicles, and regenerative therapeutics, highlighting examples involving viral infections, cancer, and neurological diseases. There is growing interest to provide personalized therapy based on individual patient and disease characteristics. Increasing evidence suggests that EV biomarkers and therapeutic approaches are ideal for personalized medicine due to the diversity and multifunctionality of EVs.
AB - Extracellular vesicles (EVs) are released from all cells in the body, forming an important intercellular communication network that contributes to health and disease. The contents of EVs are cell source-specific, inducing distinct signaling responses in recipient cells. The specificity of EVs and their accumulation in fluid spaces that are accessible for liquid biopsies make them highly attractive as potential biomarkers and therapies for disease. The duality of EVs as favorable (therapeutic) or unfavorable (pathological) messengers is context dependent and remains to be fully determined in homeostasis and various disease states. This review describes the use of EVs as biomarkers, drug delivery vehicles, and regenerative therapeutics, highlighting examples involving viral infections, cancer, and neurological diseases. There is growing interest to provide personalized therapy based on individual patient and disease characteristics. Increasing evidence suggests that EV biomarkers and therapeutic approaches are ideal for personalized medicine due to the diversity and multifunctionality of EVs.
KW - Cancer
KW - Immune response
KW - Nanomedicine
KW - Neurological disease
KW - Regenerative medicine
KW - Viruses
UR - http://www.scopus.com/inward/record.url?scp=85146183014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146183014&partnerID=8YFLogxK
U2 - 10.1016/j.mam.2022.101155
DO - 10.1016/j.mam.2022.101155
M3 - Review article
C2 - 36456416
AN - SCOPUS:85146183014
VL - 91
JO - Molecular Aspects of Medicine
JF - Molecular Aspects of Medicine
SN - 0098-2997
M1 - 101155
ER -